Skip to Main Content

Advertisement

Skip Nav Destination

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL

Blood Adv (2022) 6 (18): 5516–5525.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement